The FDA found the QUELIMMUNE pediatric registry met the study requirements tied to its original approval, completing a required follow-up. The filing reports no new sales or wider use approval, so the benefit is limited to that completed requirement.
Completing the required registry work removes an FDA follow-up task tied to QUELIMMUNE's original approval. The filing reports no new sales or wider use approval, so the positive news is limited to completing that study requirement.
Follow SeaStar Medical Holding Corp (ICU) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ICU